Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan
Satoshi Watanabe(Niigata University Medical and Dental Hospital), Tomohide Tamura(St. Luke's International Hospital), Ami Kamada(IBM Research - Tokyo), Kazumi Suzukawa(Frederick National Laboratory for Cancer Research), Yuichi Takiguchi(Sanno Medical Center), Sotaro Enatsu(Eli Lilly (Japan)), Nobuyuki Yamamoto(Wakayama Medical University), Hiroshige Yoshioka(Harbin Medical University), Keisuke Tomii(Kobe City Medical Center General Hospital), Hiroshi Sakai(Hiroshima University), Seiji Niho(Dokkyo Medical University), Yukio Hosomi(Tokyo Metropolitan Komagome Hospital), Katsuyuki Hotta(Okayama University Hospital), Makoto Nishio(Japanese Foundation For Cancer Research), Shunichi Sugawara(Sendai Kousei Hospital), Yuichiro Ohe(National Cancer Center), Terufumi Kato(Taipei Veterans General Hospital), Kazuhiko Yamada, Yukie Omori(Eli Lilly (Japan)), Mitsuhiro Takenoyama(National Hospital Organization Kyushu Cancer Center), Kazuhiko Nakagawa(Kindai University), Toshiaki Takahashi(Okayama University)
Cited by 38
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k